

# IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE

VOL 24 NO 3 SEPT 2007 ISSN 0790-9667



'Pool table' by BMc. Acrylics on board (22" x 18")

# Now your professional qualification can open even more doors

For more information on mortgages tailored exclusively for psychologists, call into your local First Active today.

At First Active we've designed our Professionals' Mortgage to be as individual as you are. This means you can look forward to a tailored mortgage; a loan that offers more flexibility than most. For example:

- You can qualify for a loan for an investment property up to 100% LTV, an amount not available to most investors;
- You can get an upfront deposit at the same rate as your mortgage;
- We can even tailor your mortgage's term and amount to suit your requirements.

So if you're a professional who is looking for a better property loan, talk to the mortgage professionals: First Active.



## First Active

**WARNING: YOUR HOME IS AT RISK IF YOU DO NOT KEEP UP PAYMENTS ON A MORTGAGE OR ANY OTHER LOAN SECURED ON IT.**

**VARIABLE RATE LOANS: THE PAYMENT RATES ON THIS HOUSING LOAN MAY BE ADJUSTED BY THE LENDER FROM TIME TO TIME.**

Lending criteria, terms and conditions apply. Over 18's only. Approval in Principle is not a commitment to lend. Mortgaged property must be within the Republic of Ireland, offer only available for purchase of completed residential properties. Not available for purchase of 1 bed or studio apartments. Only one property per customer. The maximum sum advanced is 100% of the lower of the valuation or the purchase price. The mortgage advance drawn down is for the sole purpose of financing the purchase of your home. Minimum mortgage amount is €85,000. Security and insurance are required. LTV is the Original Loan Amount as a percentage of the current market value of the property. Factors reflecting the repayment capacity of each applicant are individually assessed based on a combination of factors including qualifying income, net disposable income and existing commitments. The cost per month of a typical €100,000, 20 year tracker variable rate mortgage at **APR 5.3%** is €668.27 excluding insurance. Total Amount Repayable €160,384.83. Total cost of credit (Total Amount Repayable – Mortgage Amount) €60,384.83. If rates increase by 1%, an additional €56.84 would be payable monthly. First Active plc is regulated by the Financial Regulator.

**Editor-in-Chief:** Brian A Lawlor,  
Professor of Old Age Psychiatry,  
St Patrick's Hospital, Dublin 8

**Trainee Editor:** Brendan D Kelly,  
Consultant Psychiatrist, Department of  
Adult Psychiatry, The Mater  
Misericordiae Hospital, Dublin 7

**Production Editors:**  
Anne Henrichsen, Sonja Storm

**Advertising Manager:**  
Deirdre Gleeson

**Administrator:** Andrea McAdam

**Founding Editor:** Mark Hartman

**Associate Editor:** Ted Dinan (Cork)

**Editorial Board:** Patricia Casey  
(Dublin), Anthony Clare (Dublin),  
Stephen Cooper (Belfast),  
Michael Fitzgerald (Dublin),  
Brian Leonard (Galway),  
Roy McClelland (Belfast),  
Eadbhard O'Callaghan (Dublin),  
Brian O'Shea (Wicklow), Ian Pullen  
(Edinburgh), Philip Snaith (Leeds),  
John Waddington (Dublin),  
Richard Williams (Victoria)

**Statistical Editor:**  
Ronan Conroy (Dublin)

**Submissions & correspondence to:**  
The Editor,  
Irish Journal of Psychological Medicine,  
25 Adelaide Street, Dun Laoghaire,  
Co Dublin, Ireland.

**Telephone:** 00-353-1-2803967

**Fax:** 00-353-1-2807076

**Email:** psychological@medmedia.ie

**Website:** www.ijpm.org

**Publisher**   
MedMedia Ltd, medmedia  
25 Adelaide Street, publications  
Dun Laoghaire, Co Dublin, Ireland.  
www.medmedia.ie

**Printing:** W&G Baird Ltd

#### Subscriptions

Rates per volume of four issues  
(Mar, Jun, Sept, Dec): €155  
Incl. airmail postage internationally.

#### Subscription enquiries, orders and cheques made payable to:

MedMedia Ltd,  
25 Adelaide St, Dun Laoghaire,  
Co Dublin, Ireland  
Tel: + 353 1 280 3967  
Email: psychological@medmedia.ie  
www.medmedia.ie

#### Circulation

2,200 to 54 countries. The Journal  
participates in the World Health  
Organisation project to improve  
distribution of scientific materials on  
mental health. Publication does not  
imply endorsement. Limited photo-  
copying authorisation granted for a fee  
to Copyright Clearance Center,  
27 Congress Street, Salem, MA 01970,  
USA, or to appropriate Reproduction  
Rights Organisation; isolated non-profit,  
academic photocopying excepted.

### Editorial

#### 86 Neuroimaging in psychiatry

Dara M Cannon

### Original Papers

#### 89 A needs analysis for the provision of a speech and language therapy service to adults with mental health disorders

Irene Walsh, Julie Regan, Rebecca Sowman, Brian Parsons, A Paula McKay

#### 94 Information sharing and risk: a survey of psychiatrists

Larkin Feeney, Paul Moran

### Brief Report

#### 99 Psychological assessment of candidates for bariatric surgery

Mark Davies

### Review

#### 103 Electroconvulsive therapy: International guidelines, clinical governance and patient selection

Gavin Rush, Okka Kimmich, James V Lucey

### Historical

#### 108 One hundred years ago: The Richmond Asylum, Dublin in 1907

Brendan D Kelly

### Case reports

#### 115 Disulfiram induced peripheral neuropathy: between the devil and the deep blue sea

Caragh Behan, Abbie Lane, Mary Clarke

#### 117 Influence of ethnicity on presentation and outcome of first episode psychosis

Foluso Ademola, Kenneth Harte, Noel Kennedy

#### 119 Impact of Ramadan on the treatment of psychosis

Jannat Adil, Darina Sloan

#### 121 Clozapine induced stuttering

Brian P Hallahan, Ivan T Murray, Patrick G Doyle

### 102b John Dunne Medal

#### 107 Guidelines for Authors

#### 114 Subscriptions

#### 122 Letters to the Editor

#### 124 Book Reviews

Indexed and abstracted by BIOLOGICAL ABSTRACTS (BIOSIS Previews); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE/INIST: PASCAL; EXCERPTA MEDICA/EMBASE; INSTITUTE FOR SCIENTIFIC INFORMATION: CURRENT CONTENTS/ Social & Behavioural Sciences (Social Science CITATION INDEX, Research Alert); PSYCHOLOGICAL ABSTRACTS (PsycINFO/PsycLIT); Cumulative Index to Nursing & Allied Health Literature, Current AIDS Literature (CAB Abstracts), International Pharmaceutical Abstracts, Linguistics & Language Behaviour Abstracts, Nutrition Abstracts and Reviews, (CAB Abstracts), Referativnyi Zhurnal, Social Planning/Policy & Development Abstracts, Social Work Research & Abstracts, Sociological Abstracts.

Microfilm, microfiche & article copies from University Microfilms International, 300 North Zeeb Rd., Ann Arbor, MI 48106, USA. Journal included in the Adonis service, whereby article copies can be printed out from compact disks (CD-ROM) on demand; explanatory leaflet available from ADONIS BV, PO Box 639, 1000 AV Amsterdam, The Netherlands. Journal listed in Ulrich's International Periodicals Directory (Bowker International Serials Database), EBSCO's Selected Periodicals for the Medical and Health Sciences, & EBSCO's Librarians' Handbook.

# Keep us from drifting apart, as time goes by

## When **Change** causes **Distress** – EXELON offers

- Particular efficacy for patients displaying noticeable change<sup>1</sup>
- +
- The benefit of sustained inhibition of both AChE and BuChE<sup>2</sup>
- +
- Long-term efficacy proven over 5 years<sup>3</sup>

Bring **Stability** to her life  
– EXELON endures

For Alzheimer's Patients

**EXELON**<sup>®</sup>  
(rivastigmine)

Stability in a time of change

**PRESCRIBING INFORMATION EXELON® (rivastigmine) CAPSULES.** Presentation: 1.5mg, 3mg, 4.5mg & 6mg. **EXELON® ORAL SOLUTION (rivastigmine).** Presentation: 2mg/ml oral solution. **Indications:** Symptomatic treatment of mild to moderately severe Alzheimer's Dementia. **Dosage and administration:** Adults/Elderly: Initially 1.5mg twice a day with morning and evening meals. If well tolerated after at least two weeks of treatment, the dose should be increased to 3mg twice a day. Further increases to 4.5mg and then 6mg twice a day should be based on good tolerability after at least two weeks treatment at each dose level. The effective dose is 3 to 6mg twice a day; patients should be maintained on their highest well tolerated dose for as long as therapeutic benefit exists. The recommended maximum daily dose is 6mg twice a day. If adverse effects are observed, these may respond to omitting one or more doses; if they persist, the dose can be temporarily reduced to the previous well tolerated dose. If treatment is interrupted for longer than several days, treatment should be re-initiated at 1.5mg twice daily. Dose titration should then be carried out as described above. For patients with renal or mild-to-moderate hepatic impairment, treatment must be individually titrated based on tolerability. See full prescribing information. The capsules should be swallowed whole. The oral solution may be swallowed directly from the dosing syringe. Exelon oral solution and capsules may be interchanged at equal doses. **Children:** not recommended. **Contra-indications:** Hypersensitivity to rivastigmine, carbamate derivatives or any excipients used in Exelon. Severe liver impairment. **Precautions and warnings:** Initiation and supervision by a physician with experience of Alzheimer's Dementia. A caregiver should be available to monitor compliance. Exelon has not been investigated in patients with severe Alzheimer's Dementia, other types of dementia or other types of memory impairment. Gastrointestinal disorders such as nausea and vomiting may occur, especially in women. During therapy patient's weight should be monitored as cholinesterase inhibitors, including Exelon, have been associated with weight loss. As with other cholinesterase inhibitors, care must be taken when using Exelon in patients with sick sinus syndrome or other conduction defects, and in patients with active or a predisposition to gastric or duodenal ulcer. Care in patients with asthma and obstructive pulmonary disease. Cholinesterase inhibitors may induce or exacerbate urinary obstruction, seizures and extrapyramidal symptoms. **Pregnancy and lactation, ability to drive/operate machinery:** See full prescribing information. **Interactions:** No pharmacokinetic interaction was observed between Exelon and digoxin, warfarin, diazepam or fluoxetine. Cholinesterase inhibitors may exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia. Exelon should not be given with other cholinergic drugs and may interfere with the activity of anticholinergics. See full prescribing information. **Side-effects:** The most commonly reported adverse drug reactions are gastrointestinal, including nausea (38%) and vomiting (23%), especially during titration. Female patients in clinical studies were found to be more susceptible to gastrointestinal adverse drug reactions and weight loss. The following adverse drug reactions have been accumulated both from clinical studies with Exelon and since the introduction of Exelon into the market. Very common (>1/100, <1/10): dizziness, nausea, vomiting, diarrhoea and loss of appetite. Common (>1/1000, <1/100): agitation, confusion, headache, somnolence, tremor, abdominal pain, dyspepsia, sweating increased, fatigue, asthenia, malaise and weight loss. Uncommon (>1/10,000, <1/1000): insomnia, depression, syncope and accidental fall. Rare (>1/10,000, <1/1,000): seizures, angina pectoris, rashes, gastric and duodenal ulcers. Very rare (<1/10,000) including isolated reports: urinary infection, hallucinations, extrapyramidal symptoms, cardiac arrhythmia, hypertension, gastrointestinal haemorrhage, pancreatitis and elevated liver function test. **Overdose:** Most cases of accidental overdose have not been associated with any clinical signs or symptoms, and almost all of the patients concerned continued Exelon treatment. In overdose accompanied by severe nausea and vomiting, the use of antiemetics should be considered. In massive overdose, atropine sulphate can be used at an initial intravenous dose of 0.03 mg/kg. Use of scopolamine as an antidote is not recommended. **Presentation:** Blister strips with 14 capsules. Marketed pack sizes 28 and 56 for capsules and 120 ml Bottle packed with oral dosing syringe. **Marketing authorisation holder:** Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, United Kingdom. **Marketing authorisation number:** EU/1/98/56/1-18. Full prescribing information is available on request from: Novartis Ireland Ltd., Beech House, Beech Hill Office Campus, Clonskeagh, Dublin 4. Telephone: 01 260 12 55. **Date of last revision:** March 2004. **References:** 1. Farlow MR, et al. Response of patients with Alzheimer Disease to rivastigmine treatment is predicted by the rate of disease progression. *Arch Neurol* 2001; 58: 417-422. 2. Giacobini E. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. *J Neural Trans* 2002; 109: 1053-1065. 3. Data on file, Novartis Pharmaceuticals. N00404047

 **NOVARTIS**